VTRS BREAKING NEWS: Viatris Inc. Stock Plummets 15% Triggering Securities Class Action – Investors are Notified to Contact BFA Law by June 3, 2025 (NASDAQ:VTRS)

/EIN News/ -- NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.

Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities.   The case is pending in the U.S. District Court for the Western District of Pennsylvania and is captioned Quinn v. Viatris Inc., et al., No. 25-cv-466.

Why was Viatris Sued for Securities Fraud?

Viatris is a global healthcare company that supplies medicines to about 1 billion patients across more than 165 countries and territories. The complaint alleges that Viatris stated its facilities were in “good operating condition,” were “suitable for their intended purposes,” and that the Company was “committed to maintaining the highest quality manufacturing standards.”

However, on December 23, 2024, the Company revealed that the U.S. Food and Drug Administration had issued a Warning Letter following a failed inspection at the Company’s Indore, India, facility. Still, Viatris downplayed the situation, describing it as a “little bit of headwind” and spoke about “active discussions with the FDA” to get additional products produced at the facility exempted from the FDA’s Import Alert.

In truth, the ramifications of the failed FDA inspection resulted in a significant headwind to the Company’s financial results as it prevented the Company from manufacturing and distributing key products, including Lenalidomide.

The Stock Declines as the Truth is Revealed

On February 27, 2025, the Company released its Q4 2024 results and provided 2025 guidance. The Company revealed that the “negative impact” of the Indore facility’s failed inspection would lower 2025 revenue by “approximately $500 million” and 2025 earnings from operations by “approximately $385 million.” The Company further disclosed that the failed inspection at its Indore facility prevented it from identifying alternative supply options for Lenalidomide and from obtaining further product exemptions from the FDA. On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.

Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/viatris-inc.

What Can You Do?

If you invested in Viatris you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/viatris-inc

Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/viatris-inc

Attorney advertising. Past results do not guarantee future outcomes.